The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?

•Depending on the disease course, quality of life is affected by different symptoms.•For RRMS, gait and balance problems, and fatigue affect most quality of life.•For progressive MS, spasticity and paralysis affect most quality of life.•When measuring with a visual analogue scale, different symptoms...

Full description

Saved in:
Bibliographic Details
Published inMultiple sclerosis and related disorders Vol. 25; pp. 112 - 121
Main Authors Barin, Laura, Salmen, Anke, Disanto, Giulio, Babačić, Haris, Calabrese, Pasquale, Chan, Andrew, Kamm, Christian P., Kesselring, Jürg, Kuhle, Jens, Gobbi, Claudio, Pot, Caroline, Puhan, Milo A., von Wyl, Viktor
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.10.2018
Subjects
Online AccessGet full text
ISSN2211-0348
2211-0356
2211-0356
DOI10.1016/j.msard.2018.07.013

Cover

Abstract •Depending on the disease course, quality of life is affected by different symptoms.•For RRMS, gait and balance problems, and fatigue affect most quality of life.•For progressive MS, spasticity and paralysis affect most quality of life.•When measuring with a visual analogue scale, different symptoms gain importance. MS symptoms affect many functional domains. Knowing the specific impact of symptoms on health-related quality of life (HRQoL) is vital for successful disease and symptom management in MS. We aimed at investigating how specific MS symptoms contribute to the disease burden in individuals and from a population perspective. We included 855 Swiss Multiple Sclerosis Registry participants with a relapsing-remitting form (RRMS) or a progressive form (PMS). HRQoL was measured with the EuroQol 5-Dimension EQ-5D-index and EQ-Visual Analogue Scale (EQ-VAS) on 0–100% scales. Their associations with 20 symptoms, socio-demographic and clinical information were explored in median regression models, stratified by RRMS and PMS. We included 611 participants with RRMS and 244 with PMS. In RRMS, gait (−6.5%) and balance problems (−5.1%) had the largest EQ-5D-index reductions, and were also important at the population level (frequencies 45% and 52%). Fatigue, depression, and spasticity (frequencies 74.1%, 31%, 38%) also contributed to the population disease burden. In PMS, spasticity, paralysis, and bowel problems had the largest impact on EQ-5D-index, both at the individual and population levels. The largest impact on EQ-VAS at population level was associated in RRMS with balance problems, depression, dizziness, and spasticity, while in PMS with weakness, pain, and paralysis. While HRQoL at population level is most affected by balance problems, spasticity, and depression in RRMS, the biggest HRQoL losses in PMS are caused by spasticity, paralysis, weakness, and pain. Many symptoms with the largest effects in individuals substantially contribute to the population disease burden.
AbstractList MS symptoms affect many functional domains. Knowing the specific impact of symptoms on health-related quality of life (HRQoL) is vital for successful disease and symptom management in MS. We aimed at investigating how specific MS symptoms contribute to the disease burden in individuals and from a population perspective. We included 855 Swiss Multiple Sclerosis Registry participants with a relapsing-remitting form (RRMS) or a progressive form (PMS). HRQoL was measured with the EuroQol 5-Dimension EQ-5D-index and EQ-Visual Analogue Scale (EQ-VAS) on 0-100% scales. Their associations with 20 symptoms, socio-demographic and clinical information were explored in median regression models, stratified by RRMS and PMS. We included 611 participants with RRMS and 244 with PMS. In RRMS, gait (-6.5%) and balance problems (-5.1%) had the largest EQ-5D-index reductions, and were also important at the population level (frequencies 45% and 52%). Fatigue, depression, and spasticity (frequencies 74.1%, 31%, 38%) also contributed to the population disease burden. In PMS, spasticity, paralysis, and bowel problems had the largest impact on EQ-5D-index, both at the individual and population levels. The largest impact on EQ-VAS at population level was associated in RRMS with balance problems, depression, dizziness, and spasticity, while in PMS with weakness, pain, and paralysis. While HRQoL at population level is most affected by balance problems, spasticity, and depression in RRMS, the biggest HRQoL losses in PMS are caused by spasticity, paralysis, weakness, and pain. Many symptoms with the largest effects in individuals substantially contribute to the population disease burden.
•Depending on the disease course, quality of life is affected by different symptoms.•For RRMS, gait and balance problems, and fatigue affect most quality of life.•For progressive MS, spasticity and paralysis affect most quality of life.•When measuring with a visual analogue scale, different symptoms gain importance. MS symptoms affect many functional domains. Knowing the specific impact of symptoms on health-related quality of life (HRQoL) is vital for successful disease and symptom management in MS. We aimed at investigating how specific MS symptoms contribute to the disease burden in individuals and from a population perspective. We included 855 Swiss Multiple Sclerosis Registry participants with a relapsing-remitting form (RRMS) or a progressive form (PMS). HRQoL was measured with the EuroQol 5-Dimension EQ-5D-index and EQ-Visual Analogue Scale (EQ-VAS) on 0–100% scales. Their associations with 20 symptoms, socio-demographic and clinical information were explored in median regression models, stratified by RRMS and PMS. We included 611 participants with RRMS and 244 with PMS. In RRMS, gait (−6.5%) and balance problems (−5.1%) had the largest EQ-5D-index reductions, and were also important at the population level (frequencies 45% and 52%). Fatigue, depression, and spasticity (frequencies 74.1%, 31%, 38%) also contributed to the population disease burden. In PMS, spasticity, paralysis, and bowel problems had the largest impact on EQ-5D-index, both at the individual and population levels. The largest impact on EQ-VAS at population level was associated in RRMS with balance problems, depression, dizziness, and spasticity, while in PMS with weakness, pain, and paralysis. While HRQoL at population level is most affected by balance problems, spasticity, and depression in RRMS, the biggest HRQoL losses in PMS are caused by spasticity, paralysis, weakness, and pain. Many symptoms with the largest effects in individuals substantially contribute to the population disease burden.
MS symptoms affect many functional domains. Knowing the specific impact of symptoms on health-related quality of life (HRQoL) is vital for successful disease and symptom management in MS. We aimed at investigating how specific MS symptoms contribute to the disease burden in individuals and from a population perspective.BACKGROUNDMS symptoms affect many functional domains. Knowing the specific impact of symptoms on health-related quality of life (HRQoL) is vital for successful disease and symptom management in MS. We aimed at investigating how specific MS symptoms contribute to the disease burden in individuals and from a population perspective.We included 855 Swiss Multiple Sclerosis Registry participants with a relapsing-remitting form (RRMS) or a progressive form (PMS). HRQoL was measured with the EuroQol 5-Dimension EQ-5D-index and EQ-Visual Analogue Scale (EQ-VAS) on 0-100% scales. Their associations with 20 symptoms, socio-demographic and clinical information were explored in median regression models, stratified by RRMS and PMS.METHODSWe included 855 Swiss Multiple Sclerosis Registry participants with a relapsing-remitting form (RRMS) or a progressive form (PMS). HRQoL was measured with the EuroQol 5-Dimension EQ-5D-index and EQ-Visual Analogue Scale (EQ-VAS) on 0-100% scales. Their associations with 20 symptoms, socio-demographic and clinical information were explored in median regression models, stratified by RRMS and PMS.We included 611 participants with RRMS and 244 with PMS. In RRMS, gait (-6.5%) and balance problems (-5.1%) had the largest EQ-5D-index reductions, and were also important at the population level (frequencies 45% and 52%). Fatigue, depression, and spasticity (frequencies 74.1%, 31%, 38%) also contributed to the population disease burden. In PMS, spasticity, paralysis, and bowel problems had the largest impact on EQ-5D-index, both at the individual and population levels. The largest impact on EQ-VAS at population level was associated in RRMS with balance problems, depression, dizziness, and spasticity, while in PMS with weakness, pain, and paralysis.RESULTSWe included 611 participants with RRMS and 244 with PMS. In RRMS, gait (-6.5%) and balance problems (-5.1%) had the largest EQ-5D-index reductions, and were also important at the population level (frequencies 45% and 52%). Fatigue, depression, and spasticity (frequencies 74.1%, 31%, 38%) also contributed to the population disease burden. In PMS, spasticity, paralysis, and bowel problems had the largest impact on EQ-5D-index, both at the individual and population levels. The largest impact on EQ-VAS at population level was associated in RRMS with balance problems, depression, dizziness, and spasticity, while in PMS with weakness, pain, and paralysis.While HRQoL at population level is most affected by balance problems, spasticity, and depression in RRMS, the biggest HRQoL losses in PMS are caused by spasticity, paralysis, weakness, and pain. Many symptoms with the largest effects in individuals substantially contribute to the population disease burden.CONCLUSIONSWhile HRQoL at population level is most affected by balance problems, spasticity, and depression in RRMS, the biggest HRQoL losses in PMS are caused by spasticity, paralysis, weakness, and pain. Many symptoms with the largest effects in individuals substantially contribute to the population disease burden.
Highlights•Depending on the disease course, quality of life is affected by different symptoms. •For RRMS, gait and balance problems, and fatigue affect most quality of life. •For progressive MS, spasticity and paralysis affect most quality of life. •When measuring with a visual analogue scale, different symptoms gain importance.
Author Calabrese, Pasquale
von Wyl, Viktor
Babačić, Haris
Barin, Laura
Kuhle, Jens
Puhan, Milo A.
Salmen, Anke
Disanto, Giulio
Kesselring, Jürg
Kamm, Christian P.
Pot, Caroline
Chan, Andrew
Gobbi, Claudio
Author_xml – sequence: 1
  givenname: Laura
  orcidid: 0000-0001-8139-4686
  surname: Barin
  fullname: Barin, Laura
  email: laura.barin@uzh.ch
  organization: Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
– sequence: 2
  givenname: Anke
  surname: Salmen
  fullname: Salmen, Anke
  email: anke.salmen@insel.ch
  organization: Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland
– sequence: 3
  givenname: Giulio
  surname: Disanto
  fullname: Disanto, Giulio
  email: iulio.disanto@eoc.ch
  organization: Neurocenter of southern Switzerland, Ospedale regionale di Lugano, Lugano, Switzerland
– sequence: 4
  givenname: Haris
  surname: Babačić
  fullname: Babačić, Haris
  organization: Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
– sequence: 5
  givenname: Pasquale
  surname: Calabrese
  fullname: Calabrese, Pasquale
  email: pasquale.calabrese@unibas.ch
  organization: Neuropsychology and Behavioral Neurology Unit, Division of Molecular and Cognitive Neuroscience, Department of Psychology, University of Basel, Basel, Switzerland
– sequence: 6
  givenname: Andrew
  surname: Chan
  fullname: Chan, Andrew
  email: andrew.chan@insel.ch
  organization: Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland
– sequence: 7
  givenname: Christian P.
  surname: Kamm
  fullname: Kamm, Christian P.
  email: christian.kamm@luks.ch
  organization: Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland
– sequence: 8
  givenname: Jürg
  surname: Kesselring
  fullname: Kesselring, Jürg
  email: juerg.kesselring@kliniken-valens.ch
  organization: Department of Neurology & Neurorehabilitation, Rehabilitation Centre Kliniken Valens, Valens, Switzerland
– sequence: 9
  givenname: Jens
  surname: Kuhle
  fullname: Kuhle, Jens
  email: jens.kuhle@usb.ch
  organization: Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
– sequence: 10
  givenname: Claudio
  surname: Gobbi
  fullname: Gobbi, Claudio
  email: claudio.gobbi@eoc.ch
  organization: Neurocenter of southern Switzerland, Ospedale regionale di Lugano, Lugano, Switzerland
– sequence: 11
  givenname: Caroline
  surname: Pot
  fullname: Pot, Caroline
  email: Caroline.Pot-Kreis@chuv.ch
  organization: Laboratories of Neuroimmunology, Division of Neurology and Neuroscience Research Center, Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland
– sequence: 12
  givenname: Milo A.
  surname: Puhan
  fullname: Puhan, Milo A.
  email: miloalan.puhan@uzh.ch
  organization: Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
– sequence: 13
  givenname: Viktor
  surname: von Wyl
  fullname: von Wyl, Viktor
  email: viktor.vonwyl@uzh.ch
  organization: Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30059895$$D View this record in MEDLINE/PubMed
BookMark eNqFkk9rFTEUxYNUbK39BIJk6eaNN_M3o6hIaVWouGjFZcgkd3h5ZpIxyTx43968vtZFQZtN7uL8Tsg59zk5ct4hIS8ZFAxY-2ZTTFEGXZTAeAFdAax6Qk7KkrEVVE179Heu-TE5i3ED-bQNq1v2jBxXAE3P--aEpJs1Um0iyoh0WIJGR_1Ivy02mdkivVYWg48m0jH4iaasNk6brdGLtFQ6TWc_L1Ym4x2dMcQZVTJbfEt_ro1a07ib5uSnSCeZEgY6-Zg-viBPR2kjnt3dp-TH5cXN-ZfV1ffPX88_Xa1U3bZpNQxD17RsRGSqr8eGVyUMI3RS8a7j9cAl9kp2TDd67HU7VkzDwPNc9n1TQVedktcH3zn43wvGJCYTFVorHfolihI48Jq3Nc_SV3fSZZhQizmYSYaduE8qC_qDQOU4YsBRKJNuv52CNFYwEPtixEbcFiP2xQjoRC4ms9UD9t7-_9T7A4U5oq3BIKIy6BRqE3LIQnvzCP_hAa-scUZJ-wt3GDd-CS6nL5iIpQBxvV-Y_b4wXkFZlpAN3v3b4NHn_wBbntKl
CitedBy_id crossref_primary_10_1136_bmjopen_2022_062160
crossref_primary_10_2196_38709
crossref_primary_10_1007_s00415_019_09563_y
crossref_primary_10_1111_ene_15412
crossref_primary_10_1016_j_msard_2024_105826
crossref_primary_10_2196_52733
crossref_primary_10_1007_s00415_020_09973_3
crossref_primary_10_1016_j_prdoa_2025_100315
crossref_primary_10_1055_s_0043_1775718
crossref_primary_10_1016_j_msard_2020_102710
crossref_primary_10_1016_j_jns_2021_117437
crossref_primary_10_1177_20552076211055552
crossref_primary_10_1590_0004_282x_anp_2020_0587
crossref_primary_10_1007_s40120_023_00505_5
crossref_primary_10_7224_1537_2073_2021_079
crossref_primary_10_1016_j_jpsychores_2024_111675
crossref_primary_10_1177_20552173231208271
crossref_primary_10_1016_j_apmr_2025_01_001
crossref_primary_10_1016_j_msard_2022_103519
crossref_primary_10_1111_ene_15790
crossref_primary_10_1186_s12883_021_02344_z
crossref_primary_10_4102_ajod_v13i0_1376
crossref_primary_10_1016_j_toxcx_2020_100040
crossref_primary_10_1016_j_msard_2024_106189
crossref_primary_10_1111_hex_70033
crossref_primary_10_3389_fneur_2020_00156
crossref_primary_10_1097_NCM_0000000000000608
crossref_primary_10_1177_03080226221136816
crossref_primary_10_1016_j_msard_2023_104795
crossref_primary_10_1007_s10072_023_06983_7
crossref_primary_10_1007_s12325_023_02604_z
crossref_primary_10_1016_j_msard_2021_103429
crossref_primary_10_3389_fpubh_2021_675523
crossref_primary_10_3389_fphys_2024_1477431
crossref_primary_10_2196_40166
crossref_primary_10_1177_20552076241264389
crossref_primary_10_1136_bmjopen_2020_041249
crossref_primary_10_1371_journal_pone_0312486
crossref_primary_10_1177_2055217320964514
crossref_primary_10_1136_bmjopen_2021_051478
crossref_primary_10_1007_s40120_024_00584_y
crossref_primary_10_1016_j_rehab_2024_101898
crossref_primary_10_3389_fimmu_2022_960355
crossref_primary_10_1007_s40273_021_01081_y
crossref_primary_10_1016_j_msard_2018_11_033
crossref_primary_10_3390_brainsci11060751
crossref_primary_10_3390_medicina60060941
crossref_primary_10_1007_s10072_020_04392_8
crossref_primary_10_1080_09638288_2023_2237403
crossref_primary_10_1007_s00415_019_09500_z
crossref_primary_10_1007_s12311_020_01190_y
crossref_primary_10_30720_ered_930289
crossref_primary_10_1016_j_msard_2021_103322
crossref_primary_10_1016_j_msard_2021_103326
crossref_primary_10_1177_17562864241266113
crossref_primary_10_3389_fpsyg_2020_00504
crossref_primary_10_1016_j_dhjo_2023_101549
crossref_primary_10_1080_17582024_2024_2389037
crossref_primary_10_1016_j_msard_2023_104929
crossref_primary_10_1016_j_jtcme_2021_02_003
crossref_primary_10_1080_09638288_2024_2438254
crossref_primary_10_1016_j_msard_2020_102197
crossref_primary_10_3390_ijerph182312683
crossref_primary_10_3389_fneur_2020_00900
crossref_primary_10_1080_00207454_2019_1677648
crossref_primary_10_1016_j_invent_2019_100291
crossref_primary_10_1186_s12883_023_03423_z
crossref_primary_10_1016_j_jpsychores_2022_111078
crossref_primary_10_5606_tftrd_2022_10524
crossref_primary_10_1080_09638288_2019_1602675
crossref_primary_10_1007_s00415_019_09311_2
crossref_primary_10_1016_j_clineuro_2025_108859
crossref_primary_10_2147_PPA_S248272
crossref_primary_10_1016_j_pdpdt_2022_102823
crossref_primary_10_7224_1537_2073_2022_113
crossref_primary_10_1016_j_msard_2020_102585
crossref_primary_10_1177_03080226241280860
crossref_primary_10_1016_j_jocn_2019_03_017
crossref_primary_10_1016_j_msard_2024_105884
crossref_primary_10_2147_DNND_S395733
crossref_primary_10_3389_fneur_2021_789432
crossref_primary_10_1177_1352458520958369
crossref_primary_10_1016_j_jemep_2020_100465
crossref_primary_10_1016_j_msard_2023_104514
crossref_primary_10_1007_s11910_020_01043_5
crossref_primary_10_1186_s41687_022_00415_4
crossref_primary_10_3389_fneur_2024_1394867
crossref_primary_10_1016_j_jpsychores_2021_110402
crossref_primary_10_1016_j_clineuro_2022_107338
crossref_primary_10_1212_NXI_0000000000000914
crossref_primary_10_1016_j_msard_2022_103495
crossref_primary_10_1136_bmjno_2022_000304
crossref_primary_10_1016_j_msard_2019_101877
crossref_primary_10_1177_17562864231195513
crossref_primary_10_1016_j_msard_2019_101516
crossref_primary_10_1016_j_msard_2019_101879
crossref_primary_10_3390_children11080929
crossref_primary_10_1016_j_msard_2021_103475
crossref_primary_10_1186_s12906_021_03377_0
crossref_primary_10_1186_s41687_022_00496_1
crossref_primary_10_1007_s13167_019_00179_w
crossref_primary_10_1016_j_aimed_2022_06_001
crossref_primary_10_1055_a_1113_7702
crossref_primary_10_1016_j_msard_2021_103476
crossref_primary_10_2196_31020
crossref_primary_10_2196_13295
crossref_primary_10_12968_ijtr_2019_0097
crossref_primary_10_1016_j_msard_2020_102519
crossref_primary_10_1177_1352458518823955
crossref_primary_10_3390_jcm13102907
crossref_primary_10_3389_fimmu_2023_1168821
crossref_primary_10_1016_j_msard_2024_106165
crossref_primary_10_1111_ppc_12760
Cites_doi 10.1186/s12883-016-0763-4
10.1177/13524585070130030101
10.1046/j.1468-1331.2002.00450.x
10.1016/j.socscimed.2017.09.026
10.1007/BF02260859
10.3109/00207454.2013.812084
10.1001/jamaophthalmol.2017.4574
10.1111/j.1524-4733.2010.00727.x
10.1177/1352458517708685
10.1016/j.msard.2012.08.004
10.1016/j.msard.2017.12.006
10.1007/s40273-014-0151-0
10.1080/09638280500191753
10.1007/s11136-011-9903-x
10.1016/j.msard.2013.09.004
10.7224/1537-2073.2012-046
10.1016/0168-8510(90)90421-9
10.1017/S0317167100005989
10.1080/13548500802241902
10.1186/s12955-018-0839-5
10.1590/S0004-282X2009000500006
10.1007/s00415-017-8527-7
10.1191/1352458503ms888oa
10.3171/jns.2002.97.4.0815
10.1111/ane.12139
10.1186/s12883-017-0834-1
10.1111/j.1600-0404.2004.00257.x
10.1016/S0022-510X(02)00312-X
10.1056/NEJMoa1606468
10.1177/1352458517708097
10.1177/1352458511407951
ContentType Journal Article
Copyright 2018 Elsevier B.V.
Elsevier B.V.
Copyright © 2018 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2018 Elsevier B.V.
– notice: Elsevier B.V.
– notice: Copyright © 2018 Elsevier B.V. All rights reserved.
CorporateAuthor for the Swiss Multiple Sclerosis Registry (SMSR)
Swiss Multiple Sclerosis Registry (SMSR)
CorporateAuthor_xml – name: for the Swiss Multiple Sclerosis Registry (SMSR)
– name: Swiss Multiple Sclerosis Registry (SMSR)
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.msard.2018.07.013
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2211-0356
EndPage 121
ExternalDocumentID 30059895
10_1016_j_msard_2018_07_013
S2211034818302220
1_s2_0_S2211034818302220
Genre Journal Article
GeographicLocations Switzerland
GeographicLocations_xml – name: Switzerland
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1P~
1~.
1~5
4.4
457
4G.
53G
5VS
7-5
8P~
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABGSF
ABJNI
ABMAC
ABMZM
ABTEW
ABUDA
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADUVX
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGUBO
AGWIK
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AXJTR
BKOJK
BLXMC
BNPGV
EBS
EFJIC
EFKBS
EJD
FDB
FEDTE
FIRID
FNPLU
FYGXN
GBLVA
HVGLF
HZ~
KOM
M41
MO0
MOBAO
O-L
O9-
OAUVE
OP~
P-8
P-9
PC.
Q38
ROL
SDF
SEL
SPCBC
SSH
SSN
SSU
SSZ
T5K
Z5R
~G-
AACTN
AFKWA
AJOXV
AMFUW
RIG
AADPK
AAIAV
ABLVK
ABYKQ
AJBFU
DOVZS
EFLBG
LCYCR
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ACLOT
~HD
ID FETCH-LOGICAL-c466t-bbb7561fee1c94f58320bf07ac87784b8ae9ca71d5df9d6f31d0b8df929953073
IEDL.DBID AIKHN
ISSN 2211-0348
2211-0356
IngestDate Sun Sep 28 08:25:41 EDT 2025
Wed Feb 19 02:33:10 EST 2025
Tue Jul 01 04:16:22 EDT 2025
Thu Apr 24 22:53:25 EDT 2025
Fri Feb 23 02:11:24 EST 2024
Sun Feb 23 10:18:50 EST 2025
Tue Aug 26 20:07:29 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Keywords Patient care management
RRMS
Patient reported outcomes
EQ-5D-index
DMT
EQ-5D-5L
Regression analysis
PwMS
CIS
EQ-VAS
Quality of life
PMS
Registries
HRQoL
MICE
EQ5D
AIC
EDSS
SMSR
European Quality of Life Visual Analogue Scale
European Quality of Life 5-Dimension 5 Level version
Expanded Disability Status Scale
Clinically Isolated Syndrome
Relapsing remitting multiple sclerosis
Multivariate Imputation by Chained Equations
Progressive multiple sclerosis
Health-related quality of life
Disease-modifying Therapy
European Quality of Life 5-Dimension Index
Swiss Multiple Sclerosis Registry
Persons with multiple sclerosis
Aikake's Information Criterion
Language English
License Copyright © 2018 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c466t-bbb7561fee1c94f58320bf07ac87784b8ae9ca71d5df9d6f31d0b8df929953073
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-8139-4686
PMID 30059895
PQID 2080848648
PQPubID 23479
PageCount 10
ParticipantIDs proquest_miscellaneous_2080848648
pubmed_primary_30059895
crossref_citationtrail_10_1016_j_msard_2018_07_013
crossref_primary_10_1016_j_msard_2018_07_013
elsevier_sciencedirect_doi_10_1016_j_msard_2018_07_013
elsevier_clinicalkeyesjournals_1_s2_0_S2211034818302220
elsevier_clinicalkey_doi_10_1016_j_msard_2018_07_013
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-10-01
PublicationDateYYYYMMDD 2018-10-01
PublicationDate_xml – month: 10
  year: 2018
  text: 2018-10-01
  day: 01
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Multiple sclerosis and related disorders
PublicationTitleAlternate Mult Scler Relat Disord
PublicationYear 2018
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Motl, McAuley, Snook, Gliottoni (bib0024) 2009; 14
Kobelt, Eriksson, Phillips, Berg (bib0018) 2017; 23
Puhan, Steinmann, Kamm, Müller, Kuhle, Kurmann, Calabrese, Kesselring, von Wyl (bib0028) 2018; 148
Rafie, Young (bib0030) 2013; 19
Hopman, Coo, Edgar, McBride, Day, Brunet (bib0014) 2007; 34
van der Maas (bib0033) 2017; 17
Matter-Walstra, Klingbiel, Szucs, Pestalozzi, Schwenkglenks (bib0021) 2014; 32
Hosseini, Bourque, Hays (bib0015) 2018; 16
Campbell, Ghushchyan, Brett McQueen, Cahoon-Metzger, Livingston, Vollmer, Corboy, Miravalle, Schreiner, Porter, Nair (bib0007) 2014; 3
Montalban, Hauser, Kappos, Arnold, Bar-Or, Comi, de Seze, Giovannoni, Hartung, Hemmer, Lublin, Rammohan, Selmaj, Traboulsee, Sauter, Masterman, Fontoura, Belachew, Garren, Mairon, Chin, Wolinsky (bib0023) 2017; 376
Lobentanz, Asenbaum, Vass, Sauter, Klösch, Kolleger, Kristoferitsch, Zeitlhofer (bib0019) 2004; 110
Miller, Rudick, Baier, Cutter, Doughtery, Weinstock-Guttman, Mass, Fisher, Simonian (bib0022) 2003; 9
Spuling, Wolff, Wurm (bib0031) 2017; 19
D'Alisa, Miscio, Baudo, Simone, Tesio, Mauro (bib0008) 2006; 28
Calabrese, Kobelt, Berg, Capsa, Eriksson, the European Multiple Sclerosis Platform (bib0006) 2017; 23
Dibley, Coggrave, McClurg, Woodward, Norton (bib0009) 2017; 264
Vickrey, Hays, Harooni, Myers, Ellison (bib0034) 1995; 4
Perneger, Combescure, Courvoisier (bib0027) 2010; 13
Buhse, Banker, Clement (bib0005) 2014; 16
Jelinek, De Livera, Marck, Brown, Neate, Taylor, Weiland (bib0017) 2016; 16
Ferchichi, van der Maas (bib0011) 2015; 58S
Herdman, Gudex, Lloyd, Janssen, Kind, Parkin, Bonsel, Badia (bib0013) 2011; 20
Nogueira, Nóbrega, Lopes, Thuler, Alvarenga (bib0026) 2009; 67
Fernández, Baumstarck-Barrau, Simeoni, Auquier (bib0012) 2011; 17
Arroyo, Massana, Vila (bib0001) 2013; 123
Janardhan, Bakshi (bib0016) 2002; 205
Svensson, Borg, Nilsson (bib0032) 2014; 129
Marrie, Cutter, Tyry (bib0020) 2013; 2
Berk, Carr, Sinden, Martzke, Honey (bib0004) 2002; 97
Group (bib0010) 1990; 16
Musch, Tarver, Goren, Janz (bib0025) 2018; 135
Wang, Marrie, Fox, Tyry, Cofield, Cutter, Salter (bib0035) 2018; 20
(bib0029) 2017
Beiske, Naess, Aarseth, Andersen, Elovaara, Farkkila, Hansen, Mellgren, Sorensen, Myhr (bib0002) 2007; 13
Benito-Leon, Morales, Rivera-Navarro (bib0003) 2002; 9
Hopman (10.1016/j.msard.2018.07.013_bib0014) 2007; 34
Hosseini (10.1016/j.msard.2018.07.013_bib0015) 2018; 16
Dibley (10.1016/j.msard.2018.07.013_bib0009) 2017; 264
Perneger (10.1016/j.msard.2018.07.013_bib0027) 2010; 13
Matter-Walstra (10.1016/j.msard.2018.07.013_bib0021) 2014; 32
Rafie (10.1016/j.msard.2018.07.013_bib0030) 2013; 19
Svensson (10.1016/j.msard.2018.07.013_bib0032) 2014; 129
Janardhan (10.1016/j.msard.2018.07.013_bib0016) 2002; 205
Miller (10.1016/j.msard.2018.07.013_bib0022) 2003; 9
Herdman (10.1016/j.msard.2018.07.013_bib0013) 2011; 20
Musch (10.1016/j.msard.2018.07.013_bib0025) 2018; 135
Spuling (10.1016/j.msard.2018.07.013_bib0031) 2017; 19
Beiske (10.1016/j.msard.2018.07.013_bib0002) 2007; 13
Nogueira (10.1016/j.msard.2018.07.013_bib0026) 2009; 67
(10.1016/j.msard.2018.07.013_bib0029) 2017
Vickrey (10.1016/j.msard.2018.07.013_bib0034) 1995; 4
Wang (10.1016/j.msard.2018.07.013_bib0035) 2018; 20
Group (10.1016/j.msard.2018.07.013_bib0010) 1990; 16
Motl (10.1016/j.msard.2018.07.013_bib0024) 2009; 14
Marrie (10.1016/j.msard.2018.07.013_bib0020) 2013; 2
van der Maas (10.1016/j.msard.2018.07.013_bib0033) 2017; 17
Calabrese (10.1016/j.msard.2018.07.013_bib0006) 2017; 23
Arroyo (10.1016/j.msard.2018.07.013_bib0001) 2013; 123
Berk (10.1016/j.msard.2018.07.013_bib0004) 2002; 97
Benito-Leon (10.1016/j.msard.2018.07.013_bib0003) 2002; 9
Lobentanz (10.1016/j.msard.2018.07.013_bib0019) 2004; 110
Fernández (10.1016/j.msard.2018.07.013_bib0012) 2011; 17
D'Alisa (10.1016/j.msard.2018.07.013_bib0008) 2006; 28
Puhan (10.1016/j.msard.2018.07.013_bib0028) 2018; 148
Jelinek (10.1016/j.msard.2018.07.013_bib0017) 2016; 16
Campbell (10.1016/j.msard.2018.07.013_bib0007) 2014; 3
Kobelt (10.1016/j.msard.2018.07.013_bib0018) 2017; 23
Ferchichi (10.1016/j.msard.2018.07.013_bib0011) 2015; 58S
Buhse (10.1016/j.msard.2018.07.013_bib0005) 2014; 16
Montalban (10.1016/j.msard.2018.07.013_bib0023) 2017; 376
References_xml – volume: 376
  start-page: 209
  year: 2017
  end-page: 220
  ident: bib0023
  article-title: Ocrelizumab versus Placebo in primary progressive multiple sclerosis
  publication-title: N. Engl. J. Med.
– volume: 13
  start-page: 386
  year: 2007
  end-page: 392
  ident: bib0002
  article-title: Health-related quality of life in secondary progressive multiple sclerosis
  publication-title: Mult. Scler.
– year: 2017
  ident: bib0029
  article-title: R: A Language and Environment for Statistical Computing
– volume: 20
  start-page: 1727
  year: 2011
  end-page: 1736
  ident: bib0013
  article-title: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
  publication-title: Qual. Life Res.
– volume: 16
  year: 2018
  ident: bib0015
  article-title: Development and evaluation of a measure of patient-reported symptoms of Blepharitis
  publication-title: Health Qual. Life Outcomes
– volume: 264
  start-page: 1354
  year: 2017
  end-page: 1361
  ident: bib0009
  article-title: “It's just horrible”: a qualitative study of patients’ and carers’ experiences of bowel dysfunction in multiple sclerosis
  publication-title: J. Neurol.
– volume: 17
  start-page: 1238
  year: 2011
  end-page: 1249
  ident: bib0012
  article-title: Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires
  publication-title: Mult. Scler. J.
– volume: 4
  start-page: 187
  year: 1995
  end-page: 206
  ident: bib0034
  article-title: A health-related quality of life measure for multiple sclerosis
  publication-title: Qual. Life Res.
– volume: 97
  start-page: 815
  year: 2002
  end-page: 820
  ident: bib0004
  article-title: Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life
  publication-title: J. Neurosurg.
– volume: 3
  year: 2014
  ident: bib0007
  article-title: Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates
  publication-title: Mult. Scler. Relat. Disord.
– volume: 16
  start-page: 199
  year: 1990
  end-page: 208
  ident: bib0010
  article-title: EuroQol–a new facility for the measurement of health-related quality of life
  publication-title: Health Policy
– volume: 17
  start-page: 1
  year: 2017
  end-page: 14
  ident: bib0033
  article-title: Patient-reported questionnaires in MS rehabilitation: responsiveness and minimal important difference of the multiple sclerosis questionnaire for physiotherapists (MSQPT)
  publication-title: BMC Neurol.
– volume: 28
  start-page: 307
  year: 2006
  end-page: 314
  ident: bib0008
  article-title: Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study
  publication-title: Disabil. Rehabil.
– volume: 67
  start-page: 812
  year: 2009
  end-page: 817
  ident: bib0026
  article-title: The effect of functional limitations and fatigue on the quality of life in people with multiple sclerosis
  publication-title: Arq. Neuropsiquiatr.
– volume: 23
  start-page: 192
  year: 2017
  end-page: 203
  ident: bib0006
  article-title: New insights into the burden and costs of multiple sclerosis in Europe : Results for Switzerland
  publication-title: Mult. Scler. J.
– volume: 23
  start-page: 4
  year: 2017
  end-page: 16
  ident: bib0018
  article-title: The burden of multiple sclerosis 2015 : methods of data collection, assessment and analysis of costs, quality of life and symptoms
  publication-title: Mult. Scler. J.
– volume: 13
  start-page: 631
  year: 2010
  end-page: 635
  ident: bib0027
  article-title: General population reference values for the French version of the EuroQol EQ-5D health utility instrument
  publication-title: Value Heal.
– volume: 2
  start-page: 21
  year: 2013
  end-page: 28
  ident: bib0020
  article-title: Substantial burden of dizziness in multiple sclerosis
  publication-title: Mult. Scler. Relat. Disord.
– volume: 135
  start-page: 1345
  year: 2018
  end-page: 1351
  ident: bib0025
  article-title: Development of an 18-item measure of symptom burden in patients with glaucoma from the Collaborative Initial Glaucoma Treatment Study's symptom and health problem checklist
  publication-title: JAMA Ophthalmol.
– volume: 20
  start-page: 16
  year: 2018
  end-page: 21
  ident: bib0035
  article-title: Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis
  publication-title: Mult. Scler. Relat. Disord.
– volume: 110
  start-page: 6
  year: 2004
  end-page: 13
  ident: bib0019
  article-title: Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality
  publication-title: Acta Neurol. Scand.
– volume: 148
  start-page: w14623
  year: 2018
  ident: bib0028
  article-title: Swiss Multiple Sclerosis Registry (SMSR)
  publication-title: Swiss Med. Wkly.
– volume: 9
  start-page: 497
  year: 2002
  end-page: 502
  ident: bib0003
  article-title: Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients
  publication-title: Eur. J. Neurol.
– volume: 34
  start-page: 160
  year: 2007
  end-page: 166
  ident: bib0014
  article-title: Factors associated with health-related quality of life in multiple sclerosis
  publication-title: Can. J. Neurol. Sci.
– volume: 16
  start-page: 235
  year: 2016
  ident: bib0017
  article-title: Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis
  publication-title: BMC Neurol.
– volume: 16
  start-page: 10
  year: 2014
  end-page: 19
  ident: bib0005
  article-title: Factors associated with health-related quality of life among older people with multiple sclerosis
  publication-title: Int. J. MS Care
– volume: 19
  start-page: 85
  year: 2017
  end-page: 93
  ident: bib0031
  article-title: Response shift in self-rated health after serious health events in old age
  publication-title: Soc. Sci. Med.
– volume: 123
  start-page: 850
  year: 2013
  end-page: 858
  ident: bib0001
  article-title: Correlation between spasticity and quality of life in patients with multiple sclerosis : the CANDLE study
  publication-title: Int. J. Neurosci.
– volume: 129
  start-page: 13
  year: 2014
  end-page: 20
  ident: bib0032
  article-title: Costs and quality of life in multiple sclerosis patients with spasticity
  publication-title: Acta Neurol. Scand.
– volume: 19
  start-page: 289
  year: 2013
  ident: bib0030
  article-title: Physical factors influencing quality of life in multiple sclerosis: literature review
  publication-title: Mult. Scler. J.
– volume: 205
  start-page: 51
  year: 2002
  end-page: 58
  ident: bib0016
  article-title: Quality of life in patients with multiple sclerosis: the impact of fatigue and depression
  publication-title: J. Neurol. Sci.
– volume: 32
  start-page: 591
  year: 2014
  end-page: 599
  ident: bib0021
  article-title: Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?
  publication-title: Pharmacoeconomics
– volume: 58S
  start-page: e113
  year: 2015
  ident: bib0011
  article-title: The French version of the multiple sclerosis questionnaire for physiotherapist (MSQPT), a reliable and valid method for the evaluation of the treatment of persons with multiple sclerosis
  publication-title: Ann. Phys. Rehabil. Med.
– volume: 9
  start-page: 1
  year: 2003
  end-page: 5
  ident: bib0022
  article-title: Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis
  publication-title: Mult. Scler.
– volume: 14
  start-page: 111
  year: 2009
  end-page: 124
  ident: bib0024
  article-title: Physical activity and quality of life in multiple sclerosis: intermediary role of disability, fatigue, mood, pain, self-efficacy and social support
  publication-title: Psychol. Heal. Med.
– volume: 16
  start-page: 235
  year: 2016
  ident: 10.1016/j.msard.2018.07.013_bib0017
  article-title: Lifestyle, medication and socio-demographic determinants of mental and physical health-related quality of life in people with multiple sclerosis
  publication-title: BMC Neurol.
  doi: 10.1186/s12883-016-0763-4
– volume: 13
  start-page: 386
  year: 2007
  ident: 10.1016/j.msard.2018.07.013_bib0002
  article-title: Health-related quality of life in secondary progressive multiple sclerosis
  publication-title: Mult. Scler.
  doi: 10.1177/13524585070130030101
– volume: 9
  start-page: 497
  year: 2002
  ident: 10.1016/j.msard.2018.07.013_bib0003
  article-title: Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients
  publication-title: Eur. J. Neurol.
  doi: 10.1046/j.1468-1331.2002.00450.x
– volume: 19
  start-page: 85
  year: 2017
  ident: 10.1016/j.msard.2018.07.013_bib0031
  article-title: Response shift in self-rated health after serious health events in old age
  publication-title: Soc. Sci. Med.
  doi: 10.1016/j.socscimed.2017.09.026
– volume: 4
  start-page: 187
  year: 1995
  ident: 10.1016/j.msard.2018.07.013_bib0034
  article-title: A health-related quality of life measure for multiple sclerosis
  publication-title: Qual. Life Res.
  doi: 10.1007/BF02260859
– volume: 123
  start-page: 850
  year: 2013
  ident: 10.1016/j.msard.2018.07.013_bib0001
  article-title: Correlation between spasticity and quality of life in patients with multiple sclerosis : the CANDLE study
  publication-title: Int. J. Neurosci.
  doi: 10.3109/00207454.2013.812084
– volume: 135
  start-page: 1345
  year: 2018
  ident: 10.1016/j.msard.2018.07.013_bib0025
  article-title: Development of an 18-item measure of symptom burden in patients with glaucoma from the Collaborative Initial Glaucoma Treatment Study's symptom and health problem checklist
  publication-title: JAMA Ophthalmol.
  doi: 10.1001/jamaophthalmol.2017.4574
– volume: 148
  start-page: w14623
  year: 2018
  ident: 10.1016/j.msard.2018.07.013_bib0028
  article-title: Swiss Multiple Sclerosis Registry (SMSR)
  publication-title: Swiss Med. Wkly.
– volume: 13
  start-page: 631
  year: 2010
  ident: 10.1016/j.msard.2018.07.013_bib0027
  article-title: General population reference values for the French version of the EuroQol EQ-5D health utility instrument
  publication-title: Value Heal.
  doi: 10.1111/j.1524-4733.2010.00727.x
– volume: 23
  start-page: 192
  year: 2017
  ident: 10.1016/j.msard.2018.07.013_bib0006
  article-title: New insights into the burden and costs of multiple sclerosis in Europe : Results for Switzerland
  publication-title: Mult. Scler. J.
  doi: 10.1177/1352458517708685
– volume: 2
  start-page: 21
  year: 2013
  ident: 10.1016/j.msard.2018.07.013_bib0020
  article-title: Substantial burden of dizziness in multiple sclerosis
  publication-title: Mult. Scler. Relat. Disord.
  doi: 10.1016/j.msard.2012.08.004
– volume: 20
  start-page: 16
  year: 2018
  ident: 10.1016/j.msard.2018.07.013_bib0035
  article-title: Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis
  publication-title: Mult. Scler. Relat. Disord.
  doi: 10.1016/j.msard.2017.12.006
– volume: 32
  start-page: 591
  year: 2014
  ident: 10.1016/j.msard.2018.07.013_bib0021
  article-title: Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?
  publication-title: Pharmacoeconomics
  doi: 10.1007/s40273-014-0151-0
– volume: 19
  start-page: 289
  year: 2013
  ident: 10.1016/j.msard.2018.07.013_bib0030
  article-title: Physical factors influencing quality of life in multiple sclerosis: literature review
  publication-title: Mult. Scler. J.
– volume: 28
  start-page: 307
  year: 2006
  ident: 10.1016/j.msard.2018.07.013_bib0008
  article-title: Depression is the main determinant of quality of life in multiple sclerosis: a classification-regression (CART) study
  publication-title: Disabil. Rehabil.
  doi: 10.1080/09638280500191753
– volume: 20
  start-page: 1727
  year: 2011
  ident: 10.1016/j.msard.2018.07.013_bib0013
  article-title: Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
  publication-title: Qual. Life Res.
  doi: 10.1007/s11136-011-9903-x
– volume: 3
  year: 2014
  ident: 10.1016/j.msard.2018.07.013_bib0007
  article-title: Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates
  publication-title: Mult. Scler. Relat. Disord.
  doi: 10.1016/j.msard.2013.09.004
– year: 2017
  ident: 10.1016/j.msard.2018.07.013_bib0029
– volume: 16
  start-page: 10
  year: 2014
  ident: 10.1016/j.msard.2018.07.013_bib0005
  article-title: Factors associated with health-related quality of life among older people with multiple sclerosis
  publication-title: Int. J. MS Care
  doi: 10.7224/1537-2073.2012-046
– volume: 16
  start-page: 199
  year: 1990
  ident: 10.1016/j.msard.2018.07.013_bib0010
  article-title: EuroQol–a new facility for the measurement of health-related quality of life
  publication-title: Health Policy
  doi: 10.1016/0168-8510(90)90421-9
– volume: 34
  start-page: 160
  year: 2007
  ident: 10.1016/j.msard.2018.07.013_bib0014
  article-title: Factors associated with health-related quality of life in multiple sclerosis
  publication-title: Can. J. Neurol. Sci.
  doi: 10.1017/S0317167100005989
– volume: 14
  start-page: 111
  year: 2009
  ident: 10.1016/j.msard.2018.07.013_bib0024
  article-title: Physical activity and quality of life in multiple sclerosis: intermediary role of disability, fatigue, mood, pain, self-efficacy and social support
  publication-title: Psychol. Heal. Med.
  doi: 10.1080/13548500802241902
– volume: 16
  year: 2018
  ident: 10.1016/j.msard.2018.07.013_bib0015
  article-title: Development and evaluation of a measure of patient-reported symptoms of Blepharitis
  publication-title: Health Qual. Life Outcomes
  doi: 10.1186/s12955-018-0839-5
– volume: 67
  start-page: 812
  year: 2009
  ident: 10.1016/j.msard.2018.07.013_bib0026
  article-title: The effect of functional limitations and fatigue on the quality of life in people with multiple sclerosis
  publication-title: Arq. Neuropsiquiatr.
  doi: 10.1590/S0004-282X2009000500006
– volume: 264
  start-page: 1354
  year: 2017
  ident: 10.1016/j.msard.2018.07.013_bib0009
  article-title: “It's just horrible”: a qualitative study of patients’ and carers’ experiences of bowel dysfunction in multiple sclerosis
  publication-title: J. Neurol.
  doi: 10.1007/s00415-017-8527-7
– volume: 9
  start-page: 1
  year: 2003
  ident: 10.1016/j.msard.2018.07.013_bib0022
  article-title: Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis
  publication-title: Mult. Scler.
  doi: 10.1191/1352458503ms888oa
– volume: 97
  start-page: 815
  year: 2002
  ident: 10.1016/j.msard.2018.07.013_bib0004
  article-title: Thalamic deep brain stimulation for the treatment of tremor due to multiple sclerosis: a prospective study of tremor and quality of life
  publication-title: J. Neurosurg.
  doi: 10.3171/jns.2002.97.4.0815
– volume: 129
  start-page: 13
  year: 2014
  ident: 10.1016/j.msard.2018.07.013_bib0032
  article-title: Costs and quality of life in multiple sclerosis patients with spasticity
  publication-title: Acta Neurol. Scand.
  doi: 10.1111/ane.12139
– volume: 17
  start-page: 1
  year: 2017
  ident: 10.1016/j.msard.2018.07.013_bib0033
  article-title: Patient-reported questionnaires in MS rehabilitation: responsiveness and minimal important difference of the multiple sclerosis questionnaire for physiotherapists (MSQPT)
  publication-title: BMC Neurol.
  doi: 10.1186/s12883-017-0834-1
– volume: 110
  start-page: 6
  year: 2004
  ident: 10.1016/j.msard.2018.07.013_bib0019
  article-title: Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality
  publication-title: Acta Neurol. Scand.
  doi: 10.1111/j.1600-0404.2004.00257.x
– volume: 205
  start-page: 51
  year: 2002
  ident: 10.1016/j.msard.2018.07.013_bib0016
  article-title: Quality of life in patients with multiple sclerosis: the impact of fatigue and depression
  publication-title: J. Neurol. Sci.
  doi: 10.1016/S0022-510X(02)00312-X
– volume: 376
  start-page: 209
  year: 2017
  ident: 10.1016/j.msard.2018.07.013_bib0023
  article-title: Ocrelizumab versus Placebo in primary progressive multiple sclerosis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1606468
– volume: 58S
  start-page: e113
  year: 2015
  ident: 10.1016/j.msard.2018.07.013_bib0011
  article-title: The French version of the multiple sclerosis questionnaire for physiotherapist (MSQPT), a reliable and valid method for the evaluation of the treatment of persons with multiple sclerosis
  publication-title: Ann. Phys. Rehabil. Med.
– volume: 23
  start-page: 4
  year: 2017
  ident: 10.1016/j.msard.2018.07.013_bib0018
  article-title: The burden of multiple sclerosis 2015 : methods of data collection, assessment and analysis of costs, quality of life and symptoms
  publication-title: Mult. Scler. J.
  doi: 10.1177/1352458517708097
– volume: 17
  start-page: 1238
  year: 2011
  ident: 10.1016/j.msard.2018.07.013_bib0012
  article-title: Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires
  publication-title: Mult. Scler. J.
  doi: 10.1177/1352458511407951
SSID ssj0000651461
Score 2.4687643
Snippet •Depending on the disease course, quality of life is affected by different symptoms.•For RRMS, gait and balance problems, and fatigue affect most quality of...
Highlights•Depending on the disease course, quality of life is affected by different symptoms. •For RRMS, gait and balance problems, and fatigue affect most...
MS symptoms affect many functional domains. Knowing the specific impact of symptoms on health-related quality of life (HRQoL) is vital for successful disease...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 112
SubjectTerms Adult
Aged
Depression - etiology
Disability Evaluation
EQ5D
Fatigue - epidemiology
Fatigue - etiology
Female
Humans
Longitudinal Studies
Male
Memory Disorders - etiology
Middle Aged
Multiple Sclerosis - epidemiology
Multiple Sclerosis - physiopathology
Multiple Sclerosis - psychology
Neurology
Paresthesia - epidemiology
Paresthesia - etiology
Patient care management
Patient reported outcomes
Quality of life
Quality of Life - psychology
Registries
Regression Analysis
Sexual Dysfunction, Physiological - etiology
Surveys and Questionnaires
Switzerland - epidemiology
Visual Analog Scale
Visual Perception - physiology
Title The disease burden of Multiple Sclerosis from the individual and population perspective: Which symptoms matter most?
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2211034818302220
https://www.clinicalkey.es/playcontent/1-s2.0-S2211034818302220
https://dx.doi.org/10.1016/j.msard.2018.07.013
https://www.ncbi.nlm.nih.gov/pubmed/30059895
https://www.proquest.com/docview/2080848648
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VrYS4VOXZ5VEZiSNhE68TO72gqqJaQNtLqejNih9Rg8hDOD1w4bczTpwgBC0StyTyxIm_8czYngfAq9wgskoUUaKZjpjF5U5RFizKjUUWsbQ0w4nu9izbXLAPl-nlDpxMsTDerTLI_lGmD9I6PFmF0Vx1VbU6p37t4uNIfQorSnHdvktR24sF7B6__7g5m7daUMv66tW-zBz1G4JIM-UfGjy9aodgeC8vMeTxTNY36aibbNBBF53uw14wIsnx-J33Ycc2D-DuNhyTP4QewSfh6IWoIVCBtCXZBudBco5U2HPliI8uIWgDkmoOzCJFY0g31_Ui3a9wzCPy-arSV8R9r7u-rR2ph-ycpG5d__YRXJy--3SyiUJ5hUizLOsjpRRH66m0NtE5K1Oc27EqY15owblgCKDNdcETk5oyN1m5TkysBF6jBku9aHgMi6Zt7AEQy0UmtFmXiAbTKi4Y45nOdYwvNQmNl0CnAZU65B73JTC-ysnJ7IscUJAeBRlziSgs4fVM1I2pN25vziak5BRVinJQomq4nYz_jcy6MJedTKSjMpZ_8NsSspnyN5b9d5cvJ0aSOJn9CU3R2PbaYSPh6xtkTCzhychh86_7ugK5yNOn_9vtM7jn70ZPxOew6L9d2xdoUfXqEO68-ZEchnnzE65kIBw
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5VWwm4IN5sW8BIHIk2yTqxw6WqKqot7e6lrejNil9qKvIQSQ_99x0nThCCFolblHjixN94ZmzPA-BTphFZyfMgUlQF1OByJ7c5DTJtkEVMbHV_orvepKsL-u0yudyCwzEWxrlVetk_yPReWvs7Cz-ai6YoFmexW7u4OFKXwiqOcd2-TV1R6xlsHxyfrDbTVgtqWVe92pWZi92GINKM-Yd6T6-yRTCclxfv83hGy_t01H02aK-Ljp7BU29EkoPhO5_DlqlewKO1PyZ_CR2CT_zRC5F9oAKpLVl750FyhlTYc9ESF11C0AYkxRSYRfJKk2aq60WaX-GYX8j3q0Jdkfa2bLq6bEnZZ-ckZd12-6_g4ujr-eEq8OUVAkXTtAuklAytJ2tMpDJqE5zbobQhyxVnjFME0GQqZ5FOtM10apeRDiXHa9RgiRMNr2FW1ZV5C8QwnnKllxbRoEqGOaUsVZkK8aU6isM5xOOACuVzj7sSGD_E6GR2LXoUhENBhEwgCnP4PBE1Q-qNh5vTESkxRpWiHBSoGh4mY38jM62fy62IRBuLUPzBb3NIJ8rfWPbfXX4cGUngZHYnNHll6psWG3FX3yClfA5vBg6bft3VFch4luz8b7cf4PHqfH0qTo83J7vwxD0ZvBL3YNb9vDHv0Lrq5Hs_e-4AdGsiAg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+disease+burden+of+Multiple+Sclerosis+from+the+individual+and+population+perspective%3A+Which+symptoms+matter+most%3F&rft.jtitle=Multiple+sclerosis+and+related+disorders&rft.au=Barin%2C+Laura&rft.au=Salmen%2C+Anke&rft.au=Disanto%2C+Giulio&rft.au=Baba%C4%8Di%C4%87%2C+Haris&rft.date=2018-10-01&rft.issn=2211-0348&rft.volume=25&rft.spage=112&rft.epage=121&rft_id=info:doi/10.1016%2Fj.msard.2018.07.013&rft.externalDBID=ECK1-s2.0-S2211034818302220&rft.externalDocID=1_s2_0_S2211034818302220
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-0348&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-0348&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-0348&client=summon